sterna biologicals successfully completes Phase I development programme of SB010

Marburg, Germany, 11 September 2012 

  • SB010 was safe and well-tolerated across all dose levels

  • Phase IIa proof-of-concept trial filed with regulatory agencies

sterna biologicals GmbH & Co. KG (“sterna biologicals”) announced today that SB010, a DNAyzme-based GATA-3 antagonist for the treatment of moderate to severe Th2-driven asthma, successfully completed its comprehensive Phase I development programme.

W/O/W emulsions effectively protect DNAzymes from degradation and enhance skin penetration

Marburg, Germany, 09 May 2012

  • Superior results achieved compared to other drug carrier systems such as W/O emulsions, microemulsions, and submicron emulsions

A paper published in the International Journal of Pharmaceutics (Schmidts et al., 2012) found that the formulation employed in sterna biologicals’ drug candidate SB011 is an excellent dermal delivery system for DNAzymes.

sterna biologicals completes first-in-man study of SB010

Marburg, Germany, 27 February 2012

  • sterna biologicals completes first-in-man study of SB010, an inhaled GATA-3 antagonist for the treatment of moderate to severe Th2-driven asthma
  • SB010 was safe and well-tolerated across all dose levels

sterna biologicals GmbH & Co. KG (“sterna biologicals”) is pleased to announce successful completion of a Phase I clinical trial of its novel inhaled GATA-3 antagonist SB010 for the treatment of moderate to severe Th2-driven asthma.

Experimental data demonstrate that GATA-3-specific DNAzymes do not lead to unspecific immune cell activation

Marburg, Germany, 27 March 2012 

  • Results support favourable safety profile observed in toxicological studies and in recently completed first clinical trial of SB010

A paper published in Nucleic Acid Therapeutics (Dicke et al., 2012) found that the DNAzyme used in sterna biologicals’ drug candidate SB010, a novel inhaled GATA-3 antagonist for the treatment of moderate to severe Th2-driven asthma, does not lead to unspecific immune cell activation.

sterna biologicals commences phase I clinical trial of first-in-class DNAzyme-based GATA-3 antagonist for the treatment of moderate to severe Th2-driven asthma

Marburg, Germany, 07 November 2011

sterna biologicals GmbH & Co. KG ("sterna biologicals") is pleased to announce first dosing of its novel inhaled GATA-3 antagonist SB010 for the treatment of moderate to severe Th2-driven asthma in a phase I clinical trial. The trial is a randomised, double-blind, placebo-controlled assessment of safety and tolerability of single ascending doses of SB010 in 48 male subjects conducted by CRS Clinical Research Services Mannheim GmbH in Mannheim, Germany.